



UNITED STATES PATENT AND TRADEMARK OFFICE

CS
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/810,767	03/26/2004	Shudong Wang	CCI-029CNRCE	9076
959	7590	09/10/2007		
LAHIVE & COCKFIELD, LLP ONE POST OFFICE SQUARE BOSTON, MA 02109-2127			EXAMINER RAO, DEEPAK R	
			ART UNIT 1624	PAPER NUMBER
			MAIL DATE 09/10/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/810,767	Applicant(s) WANG ET AL.	
	Examiner Deepak Rao	Art Unit 1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 June 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5, 10-15, 17 and 19-22 ~~is~~ are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5, 10-15, 17 and 19-22 ~~is~~ are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 15, 2007 has been entered.

Claims 1-5, 10-15, 17 and 19-22 are pending in this application.

The following rejections are maintained:

1. Claims 14-15, 17 and 19 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of treating a proliferative disorder of the type disclosed in Table 3 (page 43 of the specification), does not reasonably provide enablement for a method of treating proliferative disorder generally. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The reasons provided in the previous office action are incorporated here by reference.

Applicant's arguments have been fully considered but they were not deemed to be persuasive. Applicant relies on the amendment to claim 14 which is amended to recite that the method is for treating a CDK-sensitive or CDK-dependent proliferative disorder and argues that 'no undue experimentation would be required in order to carry out the methods'. However, the experimental procedure described in Example 19 and the data in Tables 1-3 is with the biological

Art Unit: 1624

activity with respect to specific types of cancer and there is nothing in the specification how this data for a limited number of compounds of the large genus of instant claims, tested on a single class of protein, extrapolates to all the other proliferative diseases of the instant claims. Applicant did not state on record or provide any guidance that the assays provided are correlated to the clinical efficacy of the treatment of various disorders encompassed by the claims. As can be seen from specification, the *in vitro* data holds significant role in determining the dosage regimen based on the minimal effective concentration of each of the compound to achieve the desired inhibition of the enzymes.

Further, the claims continue to encompass 'a method of treating all types of cancer or leukemia' and the examiner has provided both reasoning including the nature of the invention, which is directed to an unpredictable art, citation of case law as well as relevant publication to support the reason for the rejection in the previous office action(s). Applicant has not identified any state of the art references that clearly establish correlation between the assays employed in the specification and clinical efficacy for the treatment of the claimed methods of treatment, which includes a method of treatment of cancer generally. Where the utility is unusual or difficult to treat or speculative, the examiner has authority to require evidence that tests relied on are reasonably predictive of *in vivo* efficacy by those skilled in the art.

The experimental procedure of Examples 19 and 20 and the data in Tables 1 and 3 is related to the biological activity with respect to specific types of cancer (i.e., lung cancer, colon cancer and bone cancer) and there is nothing in the specification how this data extrapolates to all the other types of cancers encompassed by the instant claims. Applicant did not state on record or provide any guidance that the assays provided are correlated to the clinical efficacy of the

Art Unit: 1624

treatment of various disorders encompassed by the claims. As can be seen from specification, the *in vitro* data holds significant role in determining the dosage regimen based on the minimal effective concentration of each of the compound to achieve the desired inhibition of the enzymes.

Applicant argues that 'the skilled person would be able to determine which CDK sensitive or dependent proliferative disorders could be treated with the anti-proliferative compounds of the present invention'. Contrary to applicant's arguments, the state of the art does not establish that a single therapeutic approach exists for the treatment of the types of cancers and/or leukemias. The development of the most efficacious strategy for the treatment of cancers is based on understanding the underlying mechanisms of carcinogenesis. This includes the knowledge that the carcinogenic process is a multi-step, multi-mechanism process and that no two cancers are alike, in spite of some apparent universal characteristics, such as their inability to have growth control, to terminally differentiate, to apoptose abnormally and to have an apparent extended or immortalized life span. Since tumor promotion phase involves multiple mechanisms, there is no existence of a single therapeutic approach. The evidence of record does not disclose any known compounds of similar structure, which have been demonstrated to treat all cancers.

Applicant's arguments have been fully considered but they were not deemed to be persuasive. Applicant cites *In re Marzocchi* and argues that 'there is nothing to controvert applicant's assertions that the claimed compounds are useful for treating CDK-sensitive and dependent disorders'. Contrary to what appellants urge by citing *In re Marzocchi*, 169 USPQ 367, it was established that the instant claims involve undue experimentation. Where the utility

Art Unit: 1624

is unusual or difficult to treat or speculative, the examiner has authority to require evidence that tests relied on are reasonably predictive of *in vivo* efficacy by those skilled in the art. See for example *In re Ruskin* 148 USPQ 221; *Ex parte Jovanovics* 211 USPQ 907.

2. Claims 1-5, 10-15, 17 and 19-22 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 6,531,479, for the reasons provided in the previous office action.

It is acknowledged that applicant 'will consider submitting a terminal disclaimer if appropriate'.

Conclusion

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period

Art Unit: 1624


will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deepak Rao whose telephone number is (571) 272-0672. The examiner can normally be reached on Monday-Friday from 8:00am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson, can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


/Deepak Rao/
Primary Examiner
Art Unit 1624

September 3, 2007